Development of a Hybrid Nanoprobe for Triple-Modality MR/SPECT/Optical Fluorescence Imaging

Research output: Contribution to journalArticle

Standard

Development of a Hybrid Nanoprobe for Triple-Modality MR/SPECT/Optical Fluorescence Imaging. / Madru, Renata; Svenmarker, Pontus; Ingvar, Christian; Ståhlberg, Freddy; Andersson-Engels, Stefan; Knutsson, Linda; Strand, Sven-Erik.

In: Diagnostics, Vol. 4, No. 1, 10.03.2014, p. 13-26.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Development of a Hybrid Nanoprobe for Triple-Modality MR/SPECT/Optical Fluorescence Imaging

AU - Madru, Renata

AU - Svenmarker, Pontus

AU - Ingvar, Christian

AU - Ståhlberg, Freddy

AU - Andersson-Engels, Stefan

AU - Knutsson, Linda

AU - Strand, Sven-Erik

PY - 2014/3/10

Y1 - 2014/3/10

N2 - Hybrid clinical imaging is an emerging technology, which improves disease diagnosis by combining already existing technologies. With the combination of high-resolution morphological imaging, i.e., MRI/CT, and high-sensitive molecular detection offered by SPECT/PET/Optical, physicians can detect disease progression at an early stage and design patient-specific treatments. To fully exploit the possibilities of hybrid imaging a hybrid probe compatible with each imaging technology is required. Here, we present a hybrid nanoprobe for triple modality MR/SPECT/Fluorescence imaging. Our imaging agent is comprised of superparamagnetic iron oxide nanoparticles (SPIONs), labeled with 99mTc and an Alexa fluorophore (AF), together forming 99mTc-AF-SPIONs. The agent was stable in human serum, and, after subcutaneous injection in the hind paw of Wistar rats, showed to be highly specific by accumulating in the sentinel lymph node. All three modalities clearly visualized the imaging agent. Our results show that a single imaging agent can be used for hybrid imaging. The use of a single hybrid contrast agent permits simultaneous hybrid imaging and, more conventionally, allow for single modality imaging at different time points. For example, a hybrid contrast agent enables pre-operative planning, intra-operative guidance, and post-operative evaluation with the same contrast agent.Keywords: SPION, SPECT, optical, fluorescence imaging, magnetic resonance imaging, MR, SLN

AB - Hybrid clinical imaging is an emerging technology, which improves disease diagnosis by combining already existing technologies. With the combination of high-resolution morphological imaging, i.e., MRI/CT, and high-sensitive molecular detection offered by SPECT/PET/Optical, physicians can detect disease progression at an early stage and design patient-specific treatments. To fully exploit the possibilities of hybrid imaging a hybrid probe compatible with each imaging technology is required. Here, we present a hybrid nanoprobe for triple modality MR/SPECT/Fluorescence imaging. Our imaging agent is comprised of superparamagnetic iron oxide nanoparticles (SPIONs), labeled with 99mTc and an Alexa fluorophore (AF), together forming 99mTc-AF-SPIONs. The agent was stable in human serum, and, after subcutaneous injection in the hind paw of Wistar rats, showed to be highly specific by accumulating in the sentinel lymph node. All three modalities clearly visualized the imaging agent. Our results show that a single imaging agent can be used for hybrid imaging. The use of a single hybrid contrast agent permits simultaneous hybrid imaging and, more conventionally, allow for single modality imaging at different time points. For example, a hybrid contrast agent enables pre-operative planning, intra-operative guidance, and post-operative evaluation with the same contrast agent.Keywords: SPION, SPECT, optical, fluorescence imaging, magnetic resonance imaging, MR, SLN

UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665510/

U2 - 10.3390/diagnostics4010013

DO - 10.3390/diagnostics4010013

M3 - Article

VL - 4

SP - 13

EP - 26

JO - Diagnostics

JF - Diagnostics

SN - 2075-4418

IS - 1

ER -